Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Autonomic and Immune Effects of Regional Anesthesia in Total Hip Arthroplasty (PENG neuromodu)

3. listopadu 2026 aktualizováno: Poznan University of Medical Sciences

Effects of Three Regional Anesthesia Strategies on Autonomic Regulation, Systemic Inflammatory Response, and Postoperative Recovery Following Elective Total Hip Arthroplasty: A Prospective Randomized Double-Blind Trial

Surgical trauma activates the sympathetic nervous system and induces a systemic inflammatory response, both of which may adversely affect postoperative recovery. Regional anesthesia has traditionally been used for perioperative analgesia; however, emerging evidence suggests that peripheral nerve blocks may also modulate autonomic and immune pathways. This prospective randomized double-blind trial aims to compare three regional anesthesia strategies in patients undergoing elective total hip arthroplasty under spinal anesthesia and to determine their effects on autonomic regulation, systemic inflammatory response, postoperative pain, opioid consumption, quality of recovery, and early functional outcomes.

Přehled studie

Postavení

Zatím nenabíráme

Intervence / Léčba

Detailní popis

Total hip arthroplasty (THA) is associated with substantial surgical trauma, resulting in activation of the sympathetic nervous system and a systemic inflammatory response that may contribute to postoperative pain, delayed functional recovery, and perioperative complications. Although regional anesthesia techniques are widely used to improve postoperative analgesia, increasing evidence suggests that they may also influence autonomic regulation and neuroimmune interactions beyond their analgesic effects. The extent to which different regional anesthesia strategies modify perioperative autonomic and inflammatory responses remains incompletely understood.

This prospective, randomized, double-blind, controlled trial aims to compare three regional analgesic strategies in patients undergoing elective primary total hip arthroplasty under spinal anesthesia: ultrasound-guided pericapsular nerve group (PENG) block, local infiltration analgesia (LIA), and the combination of PENG block with LIA. All patients will receive standardized perioperative anesthetic and multimodal analgesic management, with the regional analgesic technique being the only study intervention.

The primary objective is to determine whether different regional anesthesia strategies differentially influence perioperative autonomic regulation and systemic inflammatory response. Autonomic function will be assessed using perioperative hemodynamic parameters and vasopressor requirements, while systemic inflammatory activation will be evaluated using routinely available inflammatory biomarkers, including the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and other laboratory markers measured before and after surgery.

Secondary objectives include comparison of postoperative pain intensity at rest and during movement, opioid consumption, time to first rescue analgesia, quality of recovery assessed using the Quality of Recovery-15 (QoR-15) questionnaire, incidence of postoperative nausea and vomiting, time to first ambulation, length of hospital stay, patient satisfaction, and the incidence of postoperative complications.

The study is designed to determine whether combining peripheral nerve blockade with periarticular infiltration provides additive benefits not only for postoperative analgesia but also for modulation of autonomic-immune interactions and enhancement of postoperative recovery. The findings may improve understanding of peripheral nerve blocks as a form of perioperative neuromodulation and support optimization of regional anesthesia strategies in patients undergoing total hip arthroplasty.

Typ studie

Intervenční

Zápis (Odhadovaný)

165

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Malgorzata Reysner, MD PhD
  • Telefonní číslo: +48 61 8310122
  • E-mail: mreysner@ump.edu.pl

Studijní místa

      • Poznan, Polsko, 62-701
        • Poznan University of Medical Sciences

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 100 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Adults aged ≥18 years.
  • Scheduled for elective primary total hip arthroplasty due to primary hip osteoarthritis.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Planned spinal anesthesia with one of the study regional analgesia techniques.
  • Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Refusal or inability to provide written informed consent.
  • Revision hip arthroplasty, simultaneous bilateral hip arthroplasty, or hip arthroplasty performed for an acute fracture.
  • Known hypersensitivity to ropivacaine or other medications required for the study procedures.
  • Contraindication to spinal anesthesia, PENG block, or local infiltration analgesia, including infection at the injection site or a coagulation disorder or antithrombotic treatment that precludes safe performance of the planned procedures.
  • Pre-existing neurological or neuromuscular disease that substantially affects sensation or motor function in the operated limb or prevents reliable assessment of study outcomes.
  • Cognitive impairment or a communication disorder that prevents understanding of the study procedures or reliable completion of pain assessments.
  • A medical condition that, in the investigator's judgment, makes participation or the planned anesthetic procedures unsafe.
  • Planned use of an additional regional analgesic technique outside the study protocol.
  • Participation in another interventional study that could interfere with the assessment of the study outcomes.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: PENG Block

Ropivacaine for Pericapsular Nerve Group (PENG) Block

Ultrasound-guided single-injection pericapsular nerve group (PENG) block performed before surgery using 20ml of 0.2% ropivacaine

Ostatní jména:
  • PENG
  • Blok perikapsulární nervové skupiny
  • 0.2% Ropimol
Experimentální: Local Infiltration Analgesia (LIA)

Ropivacaine for Local Infiltration Analgesia

Local infiltration analgesia is performed intraoperatively - 20ml 0.2% ropivacaine

Ostatní jména:
  • Periarticular Infiltration Analgesia
  • 0.2% ropimol
Experimentální: Combined PENG Block + LIA

Ropivacaine for Pericapsular Nerve Group (PENG) block before surgery and Local Infiltration Analgesia (LIA)

Ultrasound-guided single-injection pericapsular nerve group (PENG) block performed before surgery using 20ml of 0.2% ropivacaine

Ostatní jména:
  • PENG
  • Blok perikapsulární nervové skupiny
  • 0.2% Ropimol

Local infiltration analgesia is performed intraoperatively - 20ml 0.2% ropivacaine

Ostatní jména:
  • Periarticular Infiltration Analgesia
  • 0.2% ropimol

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Systemic Immune-Inflammation Index (SII)
Časové okno: 24 hours after surgery

Comparison of the change in Systemic Immune-Inflammation Index from baseline to postoperative 24 hours among the three study groups.

24 hours after surgery

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Neutrophil-to-Lymphocyte Ratio (NLR)
Časové okno: 24 hours after surgery

Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups.

24 hours after surgery
Neutrophil-to-Lymphocyte Ratio (NLR)
Časové okno: 12 hours after surgery

Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups.

12 hours after surgery
Neutrophil-to-Lymphocyte Ratio (NLR)
Časové okno: 48 hours after surgery

Comparison of the change in neutrophil-to-lymphocyte ratio among the three study groups.

48 hours after surgery
Platelet-to-Lymphocyte Ratio (PLR)
Časové okno: 24 hours after surgery

Comparison of the change in platelet-to-lymphocyte ratio among the three study groups.

24 hours after surgery
Platelet-to-Lymphocyte Ratio (PLR)
Časové okno: 48 hours after surgery

Comparison of the change in platelet-to-lymphocyte ratio among the three study groups.

48 hours after surgery
Platelet-to-Lymphocyte Ratio (PLR)
Časové okno: 12 hours after surgery

Comparison of the change in platelet-to-lymphocyte ratio among the three study groups.

12 hours after surgery
Postoperative pain intensity
Časové okno: 2 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

2 hours after surgery
Postoperative pain intensity at movement
Časové okno: 2 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

2 hours after surgery
Postoperative pain intensity at movement
Časové okno: 6 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

6 hours after surgery
Postoperative pain intensity at movement
Časové okno: 12 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

12 hours after surgery
Postoperative pain intensity at movement
Časové okno: 24 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

24 hours after surgery
Postoperative pain intensity at movement
Časové okno: 48 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at movement.

48 hours after surgery
Postoperative pain intensity
Časové okno: 6 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

6 hours after surgery
Postoperative pain intensity
Časové okno: 12 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

12 hours after surgery
Postoperative pain intensity
Časové okno: 24 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

24 hours after surgery
Postoperative pain intensity
Časové okno: 48 hours after surgery

Comparison of postoperative pain intensity assessed using the Numeric Rating Scale (NRS; 0-10) at rest.

48 hours after surgery
Postoperative opioid consumption
Časové okno: 48 hours after surgery

Comparison of cumulative opioid consumption during the postoperative period, expressed as intravenous morphine milligram equivalents (MME).

48 hours after surgery
Time to first rescue analgesia
Časové okno: 48 hours after surgery

Comparison of the time from the end of surgery to the first administration of rescue opioid analgesia.

48 hours after surgery
Systemic Immune-Inflammation Index (SII)
Časové okno: 24 hours after surgery

Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups.

24 hours after surgery
Systemic Immune-Inflammation Index (SII)
Časové okno: 12 hours after surgery

Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups.

12 hours after surgery
Systemic Immune-Inflammation Index (SII)
Časové okno: 48 hours after surgery

Comparison of the change in the Systemic Immune-Inflammation Index (SII) among the three study groups.

48 hours after surgery
C-reactive protein (CRP)
Časové okno: 12 hours after surgery

Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups.

12 hours after surgery
C-reactive protein (CRP)
Časové okno: 24 hours after surgery

Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups.

24 hours after surgery
C-reactive protein (CRP)
Časové okno: 48 hours after surgery

Comparison of postoperative C-reactive protein (CRP) concentrations among the three study groups.

48 hours after surgery

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. prosince 2026

Primární dokončení (Odhadovaný)

30. prosince 2027

Dokončení studie (Odhadovaný)

1. ledna 2028

Termíny zápisu do studia

První předloženo

29. července 2026

První předloženo, které splnilo kritéria kontroly kvality

3. listopadu 2026

První zveřejněno (Aktuální)

9. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

9. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

3. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 18/2026

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

De-identified individual participant data underlying the published results will be made available upon reasonable request to the corresponding author. Data will be shared after publication of the primary study results and following approval of a methodologically sound research proposal and completion of a data sharing agreement.

Časový rámec sdílení IPD

Data will be available beginning 6 months after publication of the primary results and for a period of 5 years.

Kritéria přístupu pro sdílení IPD

Researchers who provide a methodologically sound proposal aimed at achieving the objectives of the approved proposal will be granted access. Requests should be directed to the corresponding author. A data access agreement will be required prior to data release.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ANALYTIC_CODE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit